NanoViricides is trading 5.69% lower at $1.25 in pre-market, with no clear company-specific catalyst identified.
- Shares closed at $1.33 on October 30, down 6.99% that session.
- The latest reported updates were an October 30 quarterly filing and an October 27 Ebola-trial progress update; neither was tied to this morning’s decline.
- Broader index futures are higher, so the supplied market context does not explain the decline as a same-direction move.